Skip to main content

Advertisement

SpringerLink
Log in

Comment on One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study

  • Letter to the Editor
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Saito T, Mizobuchi M, Kato T, Suzuki T, Fujiwara Y, Kanamori N, Makuuchi M, Honda H (2023) One-Year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int 112:34–44. https://doi.org/10.1007/s00223-022-01031-6

    Article  CAS  PubMed  Google Scholar 

  2. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543. https://doi.org/10.1056/NEJMoa1607948

    Article  CAS  PubMed  Google Scholar 

  3. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417–1427. https://doi.org/10.1056/NEJMoa1708322

    Article  CAS  PubMed  Google Scholar 

  4. Koos R, Brandenburg V, Mahnken AH, Schneider R, Dohmen G, Autschbach R, Marx N, Kramann R (2013) Sclerostin as a potential novel biomarker for aortic valve calcification: an in-vivo and ex-vivo study. J Heart Valve Dis 22:317–325

    PubMed  Google Scholar 

  5. Pazianas M (2022) RE: One-year romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study. Calcif Tissue Int. https://doi.org/10.1007/s00223-022-01055-y

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.com) for the English language editing.

Author information

Authors and Affiliations

  1. Division of Nephrology and Hypertension, Kawasaki Municipal Tama Hospital, 1-30-37, Syukugawara, Tama-Ku, Kawasaki, Kanagawa, 214-8525, Japan

    Masatomo Ogata, Hirofumi Sumi & Naoto Tominaga

  2. Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan

    Masatomo Ogata, Hirofumi Sumi & Naoto Tominaga

  3. Nephrology and Dialysis Center Koga, 187, Nishiushigaya, Koga, Ibaraki, 306-0233, Japan

    Kazuhiro Shiizaki

Authors
  1. Masatomo Ogata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirofumi Sumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuhiro Shiizaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Naoto Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naoto Tominaga.

Ethics declarations

Conflicts of interest

Naoto Tominaga received honorariums from Astellas Pharmaceutical Inc. and Daiichi Sankyo Co., Ltd., for being a speaker on drugs not mentioned in this letter to the editor. Masatomo Ogata, Hirofumi Sumi, and Kazuhiro Shiizaki have no conflicts of interest to declare.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors, since this is a Letter to the Editor.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ogata, M., Sumi, H., Shiizaki, K. et al. Comment on One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study. Calcif Tissue Int 113, 254–255 (2023). https://doi.org/10.1007/s00223-023-01084-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-023-01084-1

Search

Navigation